Changing the standard dose and timing of two therapies greatly cut tumor relapse and reduced side effects in mouse models of kinase mutated breast cancer and lung cancer, UT Southwestern Simmons ...
A team from IDIBELL and ICO, using a mouse orthotopic model, conducted a real-time personalized oncology study to test the best therapeutic option to treat a type of relapse sarcoma. Malignant ...
DALLAS - Aug. 9, 2019 - Changing the standard dose and timing of two therapies greatly cut tumor relapse and reduced side effects in mouse models of kinase mutated breast cancer and lung cancer, UT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results